{
  "resourceType": "MedicinalProductDefinition",
  "id": "cfsb7123030148537",
  "text": {
    "status": "generated",
    "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Generated Narrative</b></p><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Resource \"cfsb7123030148537\" </p></div><p><b>identifier</b>: id: EU/1/16/1157/003 (OFFICIAL)</p><p><b>type</b>: Marketing Authorisation <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#/#100000072062)</span></p><p><b>domain</b>: Human use <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#/#100000000012)</span></p><p><b>version</b>: 1</p><p><b>status</b>: Active <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://build.fhir.org/codesystem-publication-status.html\">PublicationStatus</a>#active)</span></p><p><b>statusDate</b>: 2015-02-07T13:28:17Z</p><p><b>description</b>: Suliqua 100 units/ml + 33 microgram/ml solution for injection in a pre-filled pen:\nEach pre-filled pen contains 300 units of insulin glargine and 100 micrograms lixisenatide in 3 ml solution.\nEach ml contains 100 units of insulin glargine and 33 micrograms lixisenatide.\nEach dose step contains 1 unit of insulin glargine and 0.33 micrograms of lixisenatide</p><p><b>route</b>: Subcutaneous use <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#/#100000073633)</span></p><p><b>indication</b>: Suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without SGLT-2 inhibitors.</p><p><b>legalStatusOfSupply</b>: Medicinal product subject to medical prescription <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#/#100000072084)</span></p><p><b>classification</b>: insulin glargine and lixisenatide <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#A10AE54)</span>, Diabetes mellitus inadequate control <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#/#100000019249)</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Suliqua 100 units/ml + 33 micrograms/ml solution for injection in a pre-filled pen</p><p><b>type</b>: Full name <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#/#220000000001)</span></p><h3>NameParts</h3><table class=\"grid\"><tr><td>-</td><td><b>Part</b></td><td><b>Type</b></td></tr><tr><td>*</td><td>Solution for injection</td><td>Pharmaceutical dose form part <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#/#220000000005)</span></td></tr></table><h3>CountryLanguages</h3><table class=\"grid\"><tr><td>-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td>*</td><td>European Union <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (unknown#eu)</span></td><td>European Union <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (unknown#eu)</span></td><td>English <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/3.0.0/CodeSystem-v3-ietf3066.html\">Tags for the Identification of Languages</a>#en)</span></td></tr></table></blockquote></div>"
  },
  "identifier": [
    {
      "use": "official",
      "system": "https://spor.ema.europa.eu/pmswi/#/",
      "value": "EU/1/16/1157/003"
    }
  ],
  "type": {
    "coding": [
      {
        "system": "https://spor.ema.europa.eu/rmswi/",
        "code": "/#100000072062"
      }
    ],
    "text": "Marketing Authorisation"
  },
  "domain": {
    "coding": [
      {
        "system": "https://spor.ema.europa.eu/rmswi/",
        "code": "/#100000000012"
      }
    ],
    "text": "Human use"
  },
  "version": "1",
  "status": {
    "coding": [
      {
        "system": "http://hl7.org/fhir/publication-status",
        "code": "active",
        "display": "Active"
      }
    ]
  },
  "statusDate": "2015-02-07T13:28:17Z",
  "description": "Suliqua 100 units/ml + 33 microgram/ml solution for injection in a pre-filled pen:\nEach pre-filled pen contains 300 units of insulin glargine and 100 micrograms lixisenatide in 3 ml solution.\nEach ml contains 100 units of insulin glargine and 33 micrograms lixisenatide.\nEach dose step contains 1 unit of insulin glargine and 0.33 micrograms of lixisenatide",
  "route": [
    {
      "coding": [
        {
          "system": "https://spor.ema.europa.eu/rmswi/",
          "code": "/#100000073633"
        }
      ],
      "text": "Subcutaneous use"
    }
  ],
  "indication": "Suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without SGLT-2 inhibitors.",
  "legalStatusOfSupply": {
    "coding": [
      {
        "system": "https://spor.ema.europa.eu/rmswi/",
        "code": "/#100000072084"
      }
    ],
    "text": "Medicinal product subject to medical prescription"
  },
  "classification": [
    {
      "coding": [
        {
          "system": "https://www.whocc.no/atc_ddd_index/",
          "code": "A10AE54"
        }
      ],
      "text": "insulin glargine and lixisenatide"
    },
    {
      "coding": [
        {
          "system": "https://spor.ema.europa.eu/rmswi/",
          "code": "/#100000019249"
        }
      ],
      "text": "Diabetes mellitus inadequate control"
    }
  ],
  "name": [
    {
      "productName": "Suliqua 100 units/ml + 33 micrograms/ml solution for injection in a pre-filled pen",
      "type": {
        "coding": [
          {
            "system": "https://spor.ema.europa.eu/rmswi/",
            "code": "/#220000000001"
          }
        ],
        "text": "Full name"
      },
      "namePart": [
        {
          "part": "Solution for injection",
          "type": {
            "coding": [
              {
                "system": "https://spor.ema.europa.eu/rmswi/",
                "code": "/#220000000005"
              }
            ],
            "text": "Pharmaceutical dose form part"
          }
        }
      ],
      "countryLanguage": [
        {
          "country": {
            "coding": [
              {
                "system": "urn:iso:std:iso:3166",
                "code": "eu"
              }
            ],
            "text": "European Union"
          },
          "jurisdiction": {
            "coding": [
              {
                "system": "urn:iso:std:iso:3166",
                "code": "eu"
              }
            ],
            "text": "European Union"
          },
          "language": {
            "coding": [
              {
                "system": "urn:ietf:bcp:47",
                "code": "en"
              }
            ],
            "text": "English"
          }
        }
      ]
    }
  ]
}